Biotech firm MetalloBio has secured $508K in Seed funding, injecting fresh capital into its mission to develop novel antimicrobial leads against multi-drug resistant 'superbugs.' The investment will fuel the company's critical efforts to combat a growing global health threat.
MetalloBio's research specifically targets pathogenic infections caused by both Gram-positive and Gram-negative bacteria. By focusing on creating new compounds, the startup aims to overcome the resistance mechanisms that render many existing treatments ineffective, offering a potential new front in the ongoing battle against these resilient pathogens.
